GET DAILY SIGNALSElutia Inc. (ELUT): Navigating Toward the $1.00 Nasdaq Threshold (+22% Move Needed)
Key Takeaways
- The $1.00 central target reflects the Nasdaq $1.00 minimum bid price threshold, a widely discussed milestone after the company received a listing deficiency notice — it is not an analyst consensus.
- Elutia Inc. (ELUT) shares recently traded near $0.82, so reaching $1.00 would require a gain of roughly 22%, a substantial move for a micro-cap.
- Only one current, verified analyst price target was found — Lake Street's $5.00 Buy (reiterated August 2026) — so no meaningful multi-analyst average exists; a prior Cantor Fitzgerald $2.00 rating is more than a year old.
- Supporting factors include a strategic refocus on breast reconstruction, a strengthened balance sheet, and a possible compliance-driven catalyst.
- Main risks include persistent operating losses, thin trading and analyst coverage, micro-cap volatility, and potential share dilution.
- For more detail, explore the company's Major News, Today's Price Move, Forecast, and Earnings pages.
- Explore Trending AI Robots for additional market insight.
How the $1.00 Target Came Into Focus
Elutia Inc. (ELUT) does not attract broad analyst attention, which means the $1.00 level stems from public discussion rather than any formal consensus. In late 2026 the company reported that its Class A common stock had traded below the Nasdaq $1.00 minimum bid price for 30 consecutive business days, resulting in a formal deficiency notice. This makes $1.00 a clear, identifiable milestone that investors continue to reference.
The sole current verified analyst target remains Lake Street's $5.00 Buy rating from Frank Takkinen, reiterated in August 2026. That single view implies roughly 500% upside and cannot be viewed as a consensus. An older Cantor Fitzgerald $2.00 Overweight rating from November 2025 is no longer current. With fewer than two usable targets available, no reliable average can be calculated, so the $1.00 compliance level serves as the realistic, publicly discussed objective.
Current Market Position and the Path Ahead
Elutia Inc. (ELUT) shares closed near $0.82 on November 13, 2026, for a market capitalization of roughly $36 million. Reaching $1.00 would require an advance of approximately 22%, a notable move for a thinly traded micro-cap. The 52-week range runs from about $0.50 to $1.39, placing $1.00 well within recent trading history rather than at an extreme.
Elutia is a commercial-stage company focused on drug-eluting biomatrix products for surgical reconstruction. It has been divesting non-core assets, including the BioEnvelope franchise and the SimpliDerm business, to concentrate on its NXT-41x antibiotic-eluting platform for breast reconstruction, with a commercial launch planned for 2027. Revenue has declined sharply year over year during the transition while losses persist, leaving the share price sensitive to execution and financing developments. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Factors That Could Support a Move Toward $1.00
- Compliance catalyst: Regaining the Nasdaq $1.00 minimum bid threshold could itself draw attention and ease delisting concerns, providing support for the share price.
- Strategic focus and funding: Divestitures have simplified the business and added cash without equity dilution, helping fund the breast reconstruction program.
- Addressable market: The NXT-41x platform targets a large U.S. surgical market, forming a key part of the longer-term case.
- Analyst conviction: Lake Street's $5.00 Buy rating reflects a view that the current valuation understates the company's potential, even though it represents only one firm's opinion.
Risks That Could Keep the Target Out of Reach
- Ongoing losses: The company remains unprofitable, with revenue falling during the divestiture-driven transition.
- Micro-cap fragility: Low liquidity and high volatility can generate sharp moves that work against shareholders.
- Dilution and financing risk: Future capital raises could pressure the share price and make $1.00 harder to sustain.
- Compliance uncertainty: There is no guarantee the shares will regain the bid threshold; a reverse split or further decline remains possible.
- Thin coverage: Minimal analyst coverage and the absence of a real consensus mean sentiment can shift on limited information.
Technical Levels and Market Structure
The $1.00 level acts as both a psychological round number and a regulatory compliance threshold, creating a meaningful resistance zone. On the downside, the 52-week low near $0.50 offers the clearest support area, while the 52-week high near $1.39 represents the next durable resistance beyond the target. Shares have been consolidating in the high-$0.70s to low-$0.90s, remaining below the $1.00 mark that anchors current discussion. From what I see, monitoring volume around these levels can provide useful context.
Time Horizon and Key Items to Watch
Analyst price targets such as Lake Street's $5.00 typically reflect a roughly 12-month research horizon, though no formal timeframe applies to the $1.00 compliance milestone. Investors should monitor Nasdaq compliance updates, quarterly earnings and revenue trends, cash runway, analyst revisions, and milestones on the NXT-41x breast reconstruction program and its planned 2027 launch. Divestiture closings and any capital-raising activity also matter directly to the share count and balance sheet. I'm watching this closely as execution details emerge.
Using AI Daily Buy/Sell Signals
Tickeron's AI Daily Buy/Sell Signals apply artificial intelligence to monitor thousands of stocks and ETFs continuously, producing Buy, Sell, or Hold signals based on evolving market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to identify opportunities, track existing positions, and detect shifting trends more efficiently than manual screening allows. For investors following volatile micro-caps like Elutia Inc. (ELUT), automated signal monitoring can help highlight when momentum and technical structure begin to change.
Final Assessment
Can Elutia Inc. (ELUT) reach $1.00? The objective rests on a real, publicly discussed milestone — Nasdaq's minimum bid price — rather than an analyst consensus, and it implies a substantial gain of about 22% from a price near $0.82. A compliance-driven catalyst, a refocused breast reconstruction strategy, and a stronger balance sheet support the case, while persistent losses, micro-cap illiquidity, dilution risk, and execution uncertainty present meaningful obstacles. Notably, the only current analyst target of $5.00 sits far higher but reflects a single firm's view, underscoring how widely opinions can diverge on a stock with such thin coverage. The next items to watch are Nasdaq compliance developments, quarterly results, and NXT-41x progress — none of which offers any guarantee about where the shares trade next.
Tickeron AI Tools in My Research
I regularly turn to Tickeron's AI Daily Buy/Sell Signals when evaluating micro-cap names like this one. The platform helps surface technical shifts and momentum changes across a broad universe of stocks, allowing me to cross-check my own analysis without replacing independent judgment. It has become a useful part of the workflow for tracking names with limited traditional coverage.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
ELUT's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for ELUT turned positive on November 09, 2026. Looking at past instances where ELUT's MACD turned positive, the stock continued to rise in 53 of 59 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
ELUT moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ELUT crossed bullishly above the 50-day moving average on November 10, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 16 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 89%.
Following a +5.25% 3-day Advance, the price is estimated to grow further. Considering data from situations where ELUT advanced for three days, in 199 of 228 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
The Aroon Indicator entered an Uptrend today. In 133 of 155 cases where ELUT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 49 cases where ELUT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ELUT as a result. In 98 of 111 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ELUT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
ELUT broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.355) is normal, around the industry mean (4.142). P/E Ratio (0.654) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.028) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. ELUT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 58 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ELUT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement